Probiotics Improve Acne Severity Scores But Don’t Cut Lesion Counts, Meta-Analysis Finds

A new systematic review and meta-analysis pooling data from 13 clinical trials and 1,453 participants finds that probiotics do not significantly reduce acne lesion counts but do produce a meaningful improvement in overall acne severity scores. The gap between those two outcomes is not a contradiction; it points to something more interesting about how probiotics may be working, and where the research needs to go next.

Oral Probiotics Lower Global Acne Severity Scores Significantly

The headline result from this meta-analysis by Julanon et al., published in the Journal of Cutaneous Medicine and Surgery in May 2026, is a significant reduction in Global Acne Grading System (GAGS) scores with oral probiotic use: a standardized mean difference of -0.47 (95% CI: -0.81 to -0.13). GAGS is a composite measure that factors in the density and type of lesions across different facial and truncal zones, giving a weighted severity score rather than a raw count. That number moved meaningfully. What did not move was the raw count of lesions: total lesion count showed an SMD of -0.22 (95% CI: -0.50 to 0.07), noninflammatory lesion count an SMD of -0.20 (95% CI: -0.48 to 0.08), and inflammatory lesion count an SMD of -0.13 (95% CI: -0.34 to 0.09). None of those cleared statistical significance.

The subgroup analysis sharpens the picture considerably. The GAGS benefit was most pronounced in patients with mild-to-moderate acne who took oral probiotics containing Lactobacillus species combined with other strains for at least 12 weeks. Shorter courses and topical-only applications did not show the same signal. Duration and formulation, in other words, matter.

Acne Affects Hundreds of Millions of People and Strains Mental Health

Acne vulgaris is not a cosmetic nuisance for a minority of teenagers. It affects approximately 9.4% of the global population, making it one of the most prevalent diseases on earth, and its burden extends well beyond the skin. A 2024 systematic review estimated that acne accounts for 5.13 million disability-adjusted life years worldwide in 2021 alone, with particularly pronounced effects on emotional and social well-being in adults and women. Social appearance anxiety, depression, and reduced quality of life track closely with severity.

That context matters for interpreting a GAGS score improvement. If the severity composite shifts downward, even without a detectable drop in raw lesion count, patients may experience real relief from the psychosocial weight of acne. A GAGS reduction is not nothing; it reflects a clinician-rated improvement in how bad the skin looks overall. The question is whether probiotics deserve credit for that change, or whether heterogeneity across trials is obscuring the signal.

How the Study Was Built: 13 Trials, 18 Arms, Three Databases

The research team searched three databases through June 30, 2024, pulling clinical trials that compared probiotics to controls and measured acne outcomes. Thirteen studies qualified, encompassing 18 study arms and 1,453 participants total. Primary outcomes were the standardized mean differences for change from baseline in total lesion count, noninflammatory lesion count, and inflammatory lesion count. Secondary outcomes included GAGS scores, Investigator's Global Assessment ratings, erythema, and sebum levels.

The theoretical rationale for testing probiotics against acne is well-established. The gut-brain-skin axis, a concept with roots stretching back decades, proposes that oral probiotics can influence systemic inflammation, oxidative stress, glycemic control, and tissue lipid content, all of which are plausible levers in acne pathogenesis. Dysregulation of the skin microbiome, including overgrowth of Cutibacterium acnes, triggers the inflammatory cascade that produces papules, pustules, and nodules. Modulating that environment from the inside out is a coherent idea. Whether it works at the scale of individual lesion counts is, after this analysis, still an open question.

High Heterogeneity Across Trials Limits What Can Be Concluded

The I² statistics tell a cautionary story. Heterogeneity for total lesion count was 75%, for noninflammatory lesion count 72%, and for inflammatory lesion count 52%. Even the GAGS result, which cleared significance, carried an I² of 67%. Those are high figures. They mean the trials were not measuring quite the same thing in quite the same way, and that pooling them smooths over meaningful variation in probiotic strains, dosages, treatment durations, patient populations, and outcome definitions.

A previous meta-analysis on probiotics and acne had suggested a potential role specifically for reducing noninflammatory lesions, positioning probiotics as a low-risk adjunctive therapy. The Julanon analysis does not flatly contradict that, but it does underscore that evidence for microbiome-targeted interventions in acne remains heterogeneous, limited by small sample sizes, short study durations, and variability in probiotic formulations. The acne field also has to contend with the fluctuating natural course of the condition: acne waxes and wanes on its own, making it harder to attribute changes to any specific intervention without long follow-up and well-matched controls.

The authors flag these limitations explicitly and caution against over-interpreting the GAGS finding in the absence of a corresponding lesion-count signal.

Lactobacillus Combinations and Skin Microbiome Timing as Next Research Targets

The subgroup results point to where more focused research should go. If the benefit concentrates in mild-to-moderate patients receiving Lactobacillus-containing multi-strain combinations for 12 weeks or longer, future trials should be designed around those parameters rather than testing heterogeneous protocols and then pooling the results. That kind of precision would reduce I² and generate cleaner effect estimates.

On the biological side, research on Cutibacterium acnes colonization dynamics suggests that early adolescence may be an optimal window for topical probiotic intervention, when the skin microbiome is still plastic and more amenable to reshaping. Whether that window also applies to oral probiotics, and whether it can be exploited clinically, remains to be tested.

For now, the evidence supports a cautious interpretation: probiotics are unlikely to replace standard acne treatments such as topical retinoids, benzoyl peroxide, or antibiotics in terms of lesion reduction. But a multi-strain oral regimen anchored on Lactobacillus, taken for at least three months, may help manage severity in patients with milder disease, and carries minimal side-effect risk. Clinicians and patients considering that option should treat the current evidence as preliminary rather than definitive.